Physician profile
James Bruce Tandy
NPI 1144325226
$3,577.82
in general payments reported to CMS, 2019-2025
21 companies · $624 in 2025
The $624 reported for 2025 was more than what 78% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $265 · 2021: $354 · 2022: $551 · 2023: $720 · 2024: $698 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $802.95 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $591.57 | 2019-2025 | Rexulti |
| Abbvie INC. | $453.67 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $297.89 | 2019-2025 | Spravato |
| Lundbeck LLC | $277.35 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $245.05 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $223.90 | 2019-2024 | Ingrezza |
| Allergan, INC. | $116.76 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.58 | 2021-2024 | Caplyta |
| Noven Therapeutics, LLC | $103.86 | 2024-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $85.11 | 2023-2025 | Auvelity |
| Alkermes, INC. | $81.94 | 2021-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $31.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.80 | 2019 | |
| Eisai INC. | $26.07 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $25.17 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.70 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.99 | 2019 | |
| Adlon Therapeutics L.P. | $13.26 | 2020 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.